TATA健康(01255)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01255 TATA健康

未开盘 08-31 15:52:55

2.020

+0.005

+0.25%

最高2.020	最低2.020	成交量0.00
今开2.020	昨收2.015	日振幅0.00%
总市值4.91亿	流通市值4.91亿	总股本2.43亿
成交额0.00	换手率0.00%	流通股本2.43亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01255","market":"HK","secType":"STK","nameCN":"TATA健康","latestPrice":2.02,"timestamp":1788162775589,"preClose":2.015,"halted":0,"volume":0,"delay":0,"changeRate":0.002481389578163719,"floatShares":242845000,"shares":243000000,"eps":0.054973,"marketStatus":"未开盘","change":0.005,"latestTime":"08-31 15:52:55","open":2.02,"high":2.02,"low":2.02,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":2.02,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-0.031,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1373472000000,"exchange":"SEHK","adjPreClose":2.015,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01255/tweets","defaultTab":"tweets","newsList":[{"id":"2663090961","title":"TATA健康(01255)发布中期业绩，股东应占亏损29万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663090961","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663090961?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:08","pubTimestamp":1787936926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，TATA健康(01255)发布2026年中期业绩，收入4727.5万港元，同比下降4.5%;公司拥有人应占亏损29万港元，上年同期溢利2059.6万港元;每股基本亏损0.001港元。期内收入同比减少，主要由于中国香港及中国澳门地区鞋类业务收入减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488848.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1602","BK1114","01255","BK1601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173062878","title":"TATA健康2026年上半年营收4727.50万港元，经调整净利润-29.00万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173062878","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173062878?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:56","pubTimestamp":1787929018,"startTime":"0","endTime":"0","summary":"TATA健康公布截至2026年6月30日止六个月的财务数据，营收约为4727.50万港元，同比下降约4.54%。经调整净利润约为-29.00万港元，相较去年同期约2059.60万港元由盈转亏。同期毛利率为65.5%，比上年同期的85.3%下降19.8个百分点。从成本结构看，销售及分销成本约1649.00万港元，较上年同期1871.40万港元降幅约11.9%；行政开支约3134.40万港元，相较上年同期3730.30万港元下降约16%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"TATA健康2026年上半年营收4727.50万港元，经调整净利润-29.00万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662509573","title":"TATA健康(01255.HK)预计中期股东应占亏损不超过150万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662509573","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662509573?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:30","pubTimestamp":1787923803,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1601","01255","BK1114","BK1602"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192698513","title":"TATA健康国际预期中期亏损大幅收窄，由1240万港元降至不超过150万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1192698513","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192698513?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:27","pubTimestamp":1787920030,"startTime":"0","endTime":"0","summary":"TATA健康国际预期集团中期应占亏损将大幅缩减，从上一年度的1240万港元降至不超过150万港元。这一显著改善表明公司财务状况正在稳步好转，亏损幅度收窄至原水平的约十分之一。据公司公告显示，此次亏损大幅减少得益于多方面因素的积极影响。业内观察人士表示，在全球经济不确定性加剧的背景下，TATA健康国际能够实现如此显著的减亏表现，反映出其在成本控制和业务优化方面采取了有效措施。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1601","BK1114","BK1602","01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136289560","title":"TATA健康（01255）修订盈利警告：上半年归母亏损预计收窄至不超150万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136289560","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136289560?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:25","pubTimestamp":1787919928,"startTime":"0","endTime":"0","summary":"TATA健康国际控股有限公司8月28日发布澄清公告称，经对集团截至2026年6月30日止六个月之最新未经审核综合财务报表及现有资料进行检视后，公司发现早前盈利警告公告存在轻微文书错误。根据最新修订，公司预期报告期内的本公司拥有人应占亏损将由原披露的约1,239.90万元减少至不超过150.00万元。除上述数据调整外，8月27日发布的盈利警告公告其他内容保持不变。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662319088","title":"TATA健康(01255.HK)发盈警 预计中期股东应占亏损约1239.9万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662319088","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662319088?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:09","pubTimestamp":1787836195,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1601","BK1602","01255","BK1114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147323941","title":"TATA健康国际：2026年上半年无子公司处置一次性收益","url":"https://stock-news.laohu8.com/highlight/detail?id=1147323941","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147323941?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:06","pubTimestamp":1787835983,"startTime":"0","endTime":"0","summary":"TATA健康国际近日披露，截至2026年6月30日的六个月内，公司并未因处置子公司而产生一次性收益。这一消息引发市场关注，投资者对此反应不一。值得注意的是，该公司在报告期内未录得任何相关非经常性损益，显示出其业务运营或并未涉及大规模资产剥离活动。分析人士指出，此类财务数据往往成为评估企业战略调整及资产整合成效的关键指标。TATA健康国际此番表态，或许暗示其在这段时期内的资本运作保持相对平稳，未出现引发财务波动的重大交易。市场观察家认为，这一情况或与公司近期的发展路径及行业环境变化存在关联。尽管缺乏一次性收益的提振，但这也可能意味着公司正采取更为审慎的经营策略，专注于核心业务的长期增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1602","BK1114","BK1601","01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180561946","title":"TATA健康（01255）发盈利警告 截至2026年6月预亏约1,239.90万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180561946","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180561946?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:06","pubTimestamp":1787835965,"startTime":"0","endTime":"0","summary":"2026年8月27日，TATA健康国际控股有限公司发布公告称，根据对截至2026年6月30日止六个月未经审核综合财务报表的初步评估，预计报告期内归属于公司拥有人之亏损约1,239.90万港元。上一年度同期公司实现归属于公司拥有人之溢利约2,059.60万港元，业绩由盈转亏。董事会指出，业绩变动主要源于2025年同期录得处置附属公司的一次性收益约3,470.00万港元，而本报告期并未产生类似收益。公司提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105182189","title":"TATA健康国际预期截至2026年6月30日止六个月股东应占亏损达1240万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105182189","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105182189?lang=zh_cn&edition=full","pubTime":"2026-08-27 21:04","pubTimestamp":1787835862,"startTime":"0","endTime":"0","summary":"TATA健康国际（01255.HK）发布公告，预期截至2026年6月30日止六个月，公司股东应占亏损约为1240万港元。这一预测数据揭示了公司在报告期内的财务表现面临挑战，较此前市场预期或呈现一定差异。具体亏损金额尚待最终审核结果确认，公司管理层表示将适时公布更详细的财务资料。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1114","BK1601","01255","BK1602"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121623852","title":"TATA健康（01255）被前独董申请清盘 涉未付薪酬约13.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121623852","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121623852?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:26","pubTimestamp":1786969602,"startTime":"0","endTime":"0","summary":"2026年8月17日，TATA健康国际控股有限公司发布公告称，已于2026年8月11日接获公司前独立非执行董事陶志强向香港特别行政区高等法院提交的清盘呈请。呈请缘于TATA健康 allegedly未能支付董事薪酬139,150.68港元。TATA健康董事会目前正在评估陶志强在任期间的表现及应付薪酬，并已就呈请事项寻求法律意见。TATA健康表示，将适时通报相关重大进展，并提醒股东及潜在投资者在买卖公司证券时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175852665","title":"TATA健康国际面临清盘呈请——2026年8月11日收到清盘申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1175852665","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175852665?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:24","pubTimestamp":1786969449,"startTime":"0","endTime":"0","summary":"TATA健康国际控股有限公司于2026年8月11日收到一份清盘呈请。这一法律行动的启动，标志着该公司可能面临强制清算程序的风险。目前，关于该呈请的具体细节尚未完全披露，市场对此消息反应谨慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1602","BK1114","BK1601","01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168483151","title":"TATA健康（01255）拟于8月28日审议2026年中期业绩及派息事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1168483151","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168483151?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:53","pubTimestamp":1786960382,"startTime":"0","endTime":"0","summary":"TATA健康国际控股有限公司（01255）8月17日公告，公司董事会已排期于2026年8月28日（星期五）召开会议，议程包括：一、审议及批准集团截至2026年6月30日止六个月之未经审计综合中期业绩；二、酌情考虑派付中期股息（如有）；三、处理其他事项。\n公告显示，截至公告日，董事会由六名成员组成，其中执行董事一名——张鸣琪先生；非执行董事一名——陈琦先生；独立非执行董事四名——黄琳女士、李亮先生、杜建峰先生及谭开国先生。\n公司提醒投资者，相关业绩及分红方案须待董事会正式审议及批准后方能确定，具体结果以后续公告为准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173098803","title":"TATA健康更新7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1173098803","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173098803?lang=zh_cn&edition=full","pubTime":"2026-08-05 14:35","pubTimestamp":1785911735,"startTime":"0","endTime":"0","summary":"TATA健康国际控股有限公司（股票代码：01255）于2026年8月5日公布了截至2026年7月31日的证券变动月报。报告显示，公司本月股本结构稳定，未发生新的发行、回购或注销等活动。\n根据公告，截至7月底，公司法定股本维持500,000,000股，面值每股0.01港元，法定股本总额500万港元。公司已发行股份总数为242,845,000股，库存股份数量为0股，与上月数字一致。本月未新增发行股份及未发生购回、注销或库藏股等变动。\n公告显示，公司确认其于报告期内继续符合香港联合交易所有限公司上市规则有关公众持股量的规定。月报由董事张鸣琪签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148969230","title":"STT与Tata Communications合资公司：在可行情况下协助客户迁移至替代容量","url":"https://stock-news.laohu8.com/highlight/detail?id=1148969230","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148969230?lang=zh_cn&edition=full","pubTime":"2026-06-24 21:50","pubTimestamp":1782309021,"startTime":"0","endTime":"0","summary":"STT与Tata Communications成立的合资公司正致力于在条件允许的情况下，协助客户将其业务迁移至替代的容量资源。此举旨在为客户提供更灵活、更具适应性的解决方案，以满足其不断变化的需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","STT","BK4135","BK1601","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU1883839398.USD","LU1894683348.USD","TAATF","LU1894683264.USD","BK4585","01255","BK1114","BK1602","LU0061475181.USD","IE00B3QW5Z07.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167334088","title":"TATA健康拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1167334088","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167334088?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:31","pubTimestamp":1777293105,"startTime":"0","endTime":"0","summary":"TATA健康于香港联合交易所上市，董事会近日宣布拟授予董事一般授权，最多可购回不超过公司已发行股本总数10%的股份。根据公告，公司当前已发行股本为242,845,000股，本次回购规模最高可达24,284,500股。本次购回授权尚待股东大会审议，其有效期将持续至下届股东周年大会结束或被股东撤回之日为止。公司亦计划在2026年5月20日召开股东周年大会，并将于5月15日至5月20日期间暂停办理股份过户登记。董事会呼吁股东适时关注后续公告及大会决议事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"TATA健康拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175539279","title":"TATA健康2025年中期营收4,211.80万港元，经调整净利润2,059.60万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1175539279","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175539279?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:37","pubTimestamp":1776991029,"startTime":"0","endTime":"0","summary":"根据公告披露，TATA健康截至2025年6月30日止六个月营收为4,211.80万港元，同比下降41.8%。同期经调整净利润2,059.60万港元，相较去年同期的亏损状况实现扭亏为盈。毛利率由上年同期的76.6%提升至82.7%。经营现金流在本期净流入474.40万港元，而去年同期为净流出1,410.90万港元。保健、金融服务及线上医疗等板块均因经营策略调整或业务停滞，在报告期内未产生收入。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181942406","title":"TATA健康2024年中期营收0.72亿港元，毛利率76.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181942406","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181942406?lang=zh_cn&edition=full","pubTime":"2026-04-24 08:32","pubTimestamp":1776990750,"startTime":"0","endTime":"0","summary":"TATA健康公告显示，截至2024年6月30日止六个月，公司实现营收约0.72亿港元，同比上一年同期的1.04亿港元下滑30.6%。同期毛利率为76.6%，较上一年同期的81.9%有所下降。经营活动所产生的现金流由上一年同期的流入474.4万港元转为本期流出1,404.2万港元。鞋类业务是主要收入来源，报告期实现收入0.72亿港元，同比减少28.2%。受市场环境与消费情绪等因素影响，其余业务板块规模较小，保健业务与线上医疗服务在报告期内均无收入进账，金融服务收入也为零。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154265011","title":"TATA健康(01255)2025年度盈利扭转 业务聚焦鞋类零售 毛利率升至80.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154265011","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154265011?lang=zh_cn&edition=full","pubTime":"2026-04-23 07:47","pubTimestamp":1776901661,"startTime":"0","endTime":"0","summary":"TATA健康国际控股有限公司于2025财政年度实现收入约9,979.90万元，同比下降23.2%。尽管全年收入下滑，毛利约8,026.40万元，毛利率由上年度的69.5%提升至80.4%。公司拥有人应占溢利约1,335.00万元，而上年度则为亏损约6,833.80万元，每股盈利由亏损0.28港元扭转至盈利0.05港元，显示公司整体盈利能力明显改善。报告期内，公司主营鞋类业务，占收入比重的100%。展望后续，公司表示将持续通过丰富产品策略与强化管控，以提升品牌竞争力和应对零售市场的环境变化。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"TATA健康(01255)2025年度盈利扭转 业务聚焦鞋类零售 毛利率升至80.4%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164624221","title":"TATA健康（01255）2024年收入降至1.24亿港元 亏损翻倍且呈负资产状态","url":"https://stock-news.laohu8.com/highlight/detail?id=1164624221","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164624221?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:59","pubTimestamp":1776819555,"startTime":"0","endTime":"0","summary":"TATA健康国际控股有限公司公布截至2024年12月31日止年度业绩。报告期内，公司收入为1.24亿港元，同比下降40.0%，主要由鞋类业务收入萎缩所致。同期毛利约为8,494.80万元，毛利率由上一年度的72.6%降至68.3%。由于销售下滑及减值开支增加，2024年除税前亏损达6,803.10万元，本公司拥有人应占亏损为6,833.80万元，同比增加逾一倍。每股基本亏损为0.28港元，上年同期则为每股盈利0.13港元。从业务板块来看，鞋类业务录得收入1.25亿港元，保健和金融等其他板块暂未形成实际收入。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"TATA健康（01255）2024年收入降至1.24亿港元 亏损翻倍且呈负资产状态","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142670318","title":"TATA健康2023年收入同比提升逾四成 毛利率下滑且净资产转负","url":"https://stock-news.laohu8.com/highlight/detail?id=1142670318","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142670318?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:49","pubTimestamp":1776818970,"startTime":"0","endTime":"0","summary":"TATA健康于截至2023年12月31日止年度实现约2.08亿港元收入，较上一年度的约1.45亿港元增长逾四成，主要受鞋类业务销售增长带动。期间毛利约1.51亿港元，同比上升约32%，但毛利率从78.8%回落至72.6%。管理层指出，香港零售市场在疫情后逐步回暖，但原材料及薪资成本上扬、店铺租金及市场推广开支维持高位，整体盈利能力受到一定程度挤压。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"TATA健康2023年收入同比提升逾四成 毛利率下滑且净资产转负","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01255"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.s-culture.com","stockEarnings":[{"period":"1week","weight":-0.0605},{"period":"1month","weight":-0.0381},{"period":"3month","weight":-0.0427},{"period":"6month","weight":0.4126},{"period":"1year","weight":5.7333},{"period":"ytd","weight":0.5538}],"compareEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":-0.0123},{"period":"3month","weight":-0.0181},{"period":"6month","weight":0.0126},{"period":"1year","weight":0.0195},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"TATA健康国际控股有限公司(原名：港大零售国际控股有限公司)是一家主要从事销售鞋类产品的投资控股公司。该公司通过四个分部运营业务。鞋类业务分部从事销售品牌名为Clarks、Josef Seibel、The Flexx和Petite Jolie的鞋类产品。金融服务业务分部提供证券的顾问服务，投资管理服务和企业融资的顾问服务。保健业务分部从事销售品牌名为AXS和Bio Lands及其他品牌的保健品以及Aptamil奶粉。线上医疗服务业务分部提供医疗服务，如医疗的顾问及咨询。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.046955},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.02637},{"month":3,"riseRate":0.545455,"avgChangeRate":0.224197},{"month":4,"riseRate":0.636364,"avgChangeRate":0.058824},{"month":5,"riseRate":0.454545,"avgChangeRate":0.033977},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.015804},{"month":7,"riseRate":0.181818,"avgChangeRate":0.066603},{"month":8,"riseRate":0.25,"avgChangeRate":-0.052544},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.077045},{"month":10,"riseRate":0.454545,"avgChangeRate":0.035169},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.031106},{"month":12,"riseRate":0.416667,"avgChangeRate":0.294855}],"exchange":"SEHK","name":"TATA健康","nameEN":"TATA HEALTH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TATA健康(01255)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供TATA健康(01255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"TATA健康,01255,TATA健康股票,TATA健康股票老虎,TATA健康股票老虎国际,TATA健康行情,TATA健康股票行情,TATA健康股价,TATA健康股市,TATA健康股票价格,TATA健康股票交易,TATA健康股票购买,TATA健康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TATA健康(01255)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供TATA健康(01255)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}